Balversa (erdafitinib) — United Healthcare

Initial criteria

• Diagnosis of urothelial carcinoma
• Disease is one of the following: locally advanced OR metastatic
• Presence of FGFR3 genetic alterations
• Disease has progressed on or after at least one line of prior systemic therapy [e.g., platinum-based chemotherapy (e.g., cisplatin, carboplatin), immune checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab)]
• One of the following: patient has received prior systemic therapy containing an immune checkpoint inhibitor (e.g., pembrolizumab, nivolumab, avelumab) OR patient is not eligible for immune checkpoint inhibitor therapy (e.g., pembrolizumab, nivolumab, avelumab)

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Balversa therapy

Approval duration

12 months